AUG 13·SEC EDGARLow
Gilliam Joseph E sold $10.8M of GKOS
Gilliam Joseph E (PRESIDENT & COO) sold 60,000 shares of GLAUKOS Corp (GKOS) at an average of $179.74 ($178.89–$180.49, $10.78M total) across 2 trades on 2026-08-11.
StockNYSE · US · USDHealthcare · Medical Devices
$GKOS
GLAUKOS Corp
Price · $GKOSvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $GKOS in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $14.5M 4 txs
Gilliam Joseph E2× · $10.8M
10b5-1 share of filings25%
Top stories · $GKOSMore →
AUG 11·SEC EDGAR
Thurman Alex R. sold $3.6M of GKOS
Thurman Alex R. (SVP & CHIEF FINANCIAL OFFICER) sold 20,000 shares of GLAUKOS Corp (GKOS) at $180.13 ($3.60M total) on 2026-08-07 under a Rule 10b5-1 trading plan.
AUG 8·simplywall.st
Is Glaukos (GKOS) Undervalued Following Record Sales And Higher 2026 Guidance?
Simply Wall St reports Glaukos (GKOS) posted record Q2 net sales, citing iDose TR and the Epioxa launch, and raised full-year 2026 net sales guidance. The stock closed at $180.02, up 17.69% over 30 days and 62.59% YTD. The article contrasts a $165 fair value narrative with an SWS DCF cash flow value of $380.09.
GKOS sentiment & insider activity
Recent GKOS coverage spans earnings, financial news and insider activity.
In the last 30 days, GKOS insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($14.5M). The most active reporter was Gilliam Joseph E, PRESIDENT & COO, with 2 filings. 25% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving GKOS
This is an insider sale, not a company fundamental update, but it can still affect near-term sentiment and positioning.
This is a routine insider sale disclosure, not a fundamental update, but it can slightly affect near-term sentiment.
Higher 2026 guidance plus record sales are near-term positive, but the article flags reimbursement and Epioxa timing as key risks to the valuation narrative.
The call provides fresh, company-specific guidance and margin/expense targets tied to iDose TR scaling and Epioxa reimbursement rollout.
The disclosure is a forward-looking commercial and pipeline update that can shift near-term expectations for glaucoma/keratoconus revenue and adoption.
alphai scores every news story that mentions GKOS with an AI model for sentiment and relevance, and aggregates insider trades from GLAUKOS Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $GKOS
Score
Gilliam Joseph E sold $10.8M of GKOS
Gilliam Joseph E (PRESIDENT & COO) sold 60,000 shares of GLAUKOS Corp (GKOS) at an average of $179.74 ($178.89–$180.49, $10.78M total) across 2 trades on 2026-08-11.
2 min readThurman Alex R. sold $3.6M of GKOS
Thurman Alex R. (SVP & CHIEF FINANCIAL OFFICER) sold 20,000 shares of GLAUKOS Corp (GKOS) at $180.13 ($3.60M total) on 2026-08-07 under a Rule 10b5-1 trading plan.
1 min readIs Glaukos (GKOS) Undervalued Following Record Sales And Higher 2026 Guidance?
Simply Wall St reports Glaukos (GKOS) posted record Q2 net sales, citing iDose TR and the Epioxa launch, and raised full-year 2026 net sales guidance. The stock closed at $180.02, up 17.69% over 30 days and 62.59% YTD. The article contrasts a $165 fair value narrative with an SWS DCF cash flow value of $380.09.
6 min read
Glaukos (GKOS) Q2 2026 Earnings Call Transcript
Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.
7 min read
Glaukos posts investor presentation outlining iDose TR, Epioxa launch and pipeline depth
Glaukos (GKOS) filed and posted an investor presentation outlining progress for iDose TR, including FDA re-administration approval in Jan 2026 for up to 3 years of therapy, and the March 2026 launch of Epioxa for keratoconus. It also cites a pipeline of 13 programs and 2026 revenue guidance midpoint of about $690M, with $289M cash and no debt as of 6/30/2026.
1 min readH.C. Wainwright raises Glaukos stock price target on strong results
H.C. Wainwright raised its Glaukos (NYSE:GKOS) price target to $195 from $168 and kept a Buy rating after Glaukos reported Q2 2026 results. Revenue was $185.6M, up 49.5% YoY, and glaucoma revenue was $155.2M. Glaukos raised full-year 2026 net sales guidance to $680M-$700M.
4 min readWhy Glaukos (GKOS) Is Up 10.8% After Raising 2026 Sales Guidance And Advancing PRESERFLO Study
Simply Wall St reports that Glaukos (GKOS) rose 10.8% after the company raised its 2026 sales guidance and advanced its PRESERFLO study. The piece also references other fair value estimates and notes potential upside and a warning sign, based on historical data and analyst forecasts.
2 min readGlaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up
Glaukos (GKOS) reported Q2 2026 adjusted loss of 14 cents per share, better than the Zacks Consensus loss of 28 cents. Revenue rose to $185.6 million, up 50% year over year, beating the consensus by 24.1%. Management raised 2026 net sales guidance to $680 million to $700 million. Shares rose 9.8% in after-hours.
6 min readTruist raises Glaukos stock price target to $215 on higher estimates By Investing.com
Truist Securities raised its price target for Glaukos (NYSE:GKOS) to $215 from $180 and kept a Buy rating. The stock trades at $161.66 near its 52-week high. Truist cited higher estimates, including valuation contributions from iDose and Corneal Health, and noted increased confidence after a J-code secured July 1, 2026. Glaukos reported Q2 2026 results and raised its full-year sales outlook.
2 min readGlaukos Q2 Earnings Call Highlights
Glaukos (NYSE:GKOS) reported Q2 updates on iDose TR, including acceleration across Medicare Administrative Contractor regions and no material demand pull-forward from proposed LCDs. International glaucoma revenue rose to $36.6M (+17%); corneal health revenue rose 48% to $30.4M with ~$11M Epioxa. Gross margin was ~85%. Full-year targets: gross margin 84% to 86%, corneal health growth ~20%.
4 min read